121 related articles for article (PubMed ID: 27011118)
21. Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies.
Malissen B; Rebai N; Liabeuf A; Mawas C
Eur J Immunol; 1982 Sep; 12(9):739-47. PubMed ID: 6982820
[TBL] [Abstract][Full Text] [Related]
22. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
23. Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.
Pion S; Fontaine P; Baron C; Gyger M; Perreault C
J Clin Invest; 1995 Apr; 95(4):1561-8. PubMed ID: 7706462
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
25. The requirements for triggering of lysis by cytolytic T lymphocyte clones. II. Cyclosporin A inhibits TCR-mediated exocytosis by only selectively inhibits TCR-mediated lytic activity by cloned CTL.
Lancki DW; Kaper BP; Fitch FW
J Immunol; 1989 Jan; 142(2):416-24. PubMed ID: 2492047
[TBL] [Abstract][Full Text] [Related]
26. T3 monoclonal antibody activation of nonspecific cytolysis: a mechanism of CTL inhibition.
Mentzer SJ; Barbosa JA; Burakoff SJ
J Immunol; 1985 Jul; 135(1):34-8. PubMed ID: 2582036
[TBL] [Abstract][Full Text] [Related]
27. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
28. Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.
Plessers J; Dekimpe E; Van Woensel M; Roobrouck VD; Bullens DM; Pinxteren J; Verfaillie CM; Van Gool SW
Stem Cells Transl Med; 2016 Dec; 5(12):1607-1619. PubMed ID: 27465071
[TBL] [Abstract][Full Text] [Related]
29. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.
Bundell CS; Jackaman C; Suhrbier A; Robinson BW; Nelson DJ
Cancer Immunol Immunother; 2006 Aug; 55(8):933-47. PubMed ID: 16283304
[TBL] [Abstract][Full Text] [Related]
30. Production and the characterization of monoclonal antibody against CD43, K06.
Park WS; Chae JS; Jung KC; Choi WJ; Kook MC; Bae Y
Tissue Antigens; 2004 Jan; 63(1):46-53. PubMed ID: 14651523
[TBL] [Abstract][Full Text] [Related]
31. Human lymphocyte function associated antigen-1 (LFA-1): identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity.
Ware CF; Sanchez-Madrid F; Krensky AM; Burakoff SJ; Strominger JL; Springer TA
J Immunol; 1983 Sep; 131(3):1182-8. PubMed ID: 6193178
[TBL] [Abstract][Full Text] [Related]
32. Core 2-containing O-glycans on CD43 are preferentially expressed in the memory subset of human CD4 T cells.
Mukasa R; Homma T; Ohtsuki T; Hosono O; Souta A; Kitamura T; Fukuda M; Watanabe S; Morimoto C
Int Immunol; 1999 Feb; 11(2):259-68. PubMed ID: 10069424
[TBL] [Abstract][Full Text] [Related]
33. Perforin-mediated CTL cytolysis counteracts direct cell-cell spread of Listeria monocytogenes.
San Mateo LR; Chua MM; Weiss SR; Shen H
J Immunol; 2002 Nov; 169(9):5202-8. PubMed ID: 12391238
[TBL] [Abstract][Full Text] [Related]
34. A unique murine CD43 epitope Lp-3: distinct distribution from another CD43 epitope S7.
Shiota J; Nishimura H; Okamoto H; Yu B; Hattori S; Abe M; Okada T; Nozawa S; Tsurui H; Hirose S
Cell Immunol; 1994 May; 155(2):402-13. PubMed ID: 7514104
[TBL] [Abstract][Full Text] [Related]
35. Differential expression of CD43 isoforms on murine T cells and their relationship to acute intestinal graft versus host disease: studies using enhanced-green fluorescent protein transgenic mice.
Bagriaçik EU; Armstrong MD; Okabe M; Klein JR
Int Immunol; 1999 Oct; 11(10):1651-62. PubMed ID: 10508183
[TBL] [Abstract][Full Text] [Related]
36. Cancer-associated CD43 glycoforms as target of immunotherapy.
Tuccillo FM; Palmieri C; Fiume G; de Laurentiis A; Schiavone M; Falcone C; Iaccino E; Galandrini R; Capuano C; Santoni A; D'Armiento FP; Arra C; Barbieri A; Dal Piaz F; Venzon D; Bonelli P; Buonaguro FM; Scala I; Mallardo M; Quinto I; Scala G
Mol Cancer Ther; 2014 Mar; 13(3):752-62. PubMed ID: 24356816
[TBL] [Abstract][Full Text] [Related]
37. Expression characteristics and stimulatory functions of CD43 in human CD4+ memory T cells: analysis using a monoclonal antibody to CD43 that has a novel lineage specificity.
Kyoizumi S; Ohara T; Kusunoki Y; Hayashi T; Koyama K; Tsuyama N
J Immunol; 2004 Jun; 172(12):7246-53. PubMed ID: 15187099
[TBL] [Abstract][Full Text] [Related]
38. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. I. Isolation of a selectively resistant variant tumor subclone.
Green WR
Eur J Immunol; 1983 Nov; 13(11):863-70. PubMed ID: 6196206
[TBL] [Abstract][Full Text] [Related]
39. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes.
Al Qudaihi G; Lehe C; Dickinson A; Eltayeb K; Rasheed W; Chaudhri N; Aljurf M; Dermime S
Hematol Oncol Stem Cell Ther; 2010; 3(1):24-33. PubMed ID: 20231810
[TBL] [Abstract][Full Text] [Related]
40. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
